Article Text

Download PDFPDF
Drug induced pseudolymphoma secondary to ethosuximide
  1. M R Masruha1,
  2. C M Marques1,
  3. L C P Vilanova1,
  4. M T de Seixas Alves2,
  5. M F P Peres3,
  6. M G Rodrigues4
  1. 1Department of Neurology and Neurosurgery, Federal University of São Paulo, São Paulo, Brazil
  2. 2Department of Pathology, Federal University of São Paulo
  3. 3Research and Teaching Institute, Albert Einstein Hospital, São Paulo
  4. 4Department of Paediatrics, Federal University of Espírito Santo, Espírito Santo, Brazil
  1. Correspondence to:
 Dr Marcelo Rodrigues Masruha
 Division of Child Neurology, Department of Neurology and Neurosurgery, Botucatu Street 720, Federal University of São Paulo, São Paulo 04023-9000, Brazil; mmasruhaig.com.br

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Ethosuximide is an antiepileptic succinimide, widely used in the treatment of absence seizures. Haemopoietic complications associated with the administration of this drug have included leucopenia, agranulocytosis, pancytopenia with or without bone marrow suppression, and eosinophilia.1 We report a patient with pseudolymphoma induced by ethosuximide, a complication never reported previously.

Case report

A 12 year old boy presented with a two months history of fever, weight loss (3 kg), and non-painful swellings on the neck, axillae, and both inguinal regions. The patient had been on ethosuximide for three months for childhood absence epilepsy. It was being given at a dose of 30 mg/kg/day, in three divided doses, and the seizures had been under reasonable control.

Physical examination on presentation revealed enlarged lymph nodes on the both sides of the neck, axillae, and inguinal regions. All the nodes were non-tender, firm, measuring 1 to …

View Full Text

Footnotes

  • Competing interests: none declared